Details of the Drug Formulations

General Information of Drug (ID: DMQ2FKJ)

Drug Name
Teriflunomide Drug Info
Indication
Disease Entry ICD 11 Status REF
Hyperlipidaemia 5C80 Approved [1]
Lupus nephritis 4A40.0Y Approved [2]
Multiple sclerosis 8A40 Approved [3]
Psoriatic arthritis FA21 Approved [2]
Rheumatoid arthritis FA20 Phase 3 [3]
Hepatitis B virus infection 1E51.0 Phase 1 [1]
Cross-matching ID
PubChem CID
54684141
ChEBI ID
CHEBI:68540
CAS Number
163451-81-8
TTD ID
D07QFP
VARIDT ID
DR00092
ACDINA ID
D00665

Full List of Drug Formulations Containing This Drug

Teriflunomide 7 mg tablet
Company Formulation ID FDA Description
Genzyme Corporation F21000 Lactose monohydrate; Fd&c blue no. 2; Magnesium stearate; Ferric oxide yellow; Talc; Titanium dioxide; Hydroxypropyl cellulose (1200000 mw); Hypromellose, unspecified; Microcrystalline cellulose; Polyethylene glycol, unspecified; Sodium starch glycolate type a corn; Starch, corn
------------------------------------------------------------------------------------
Teriflunomide 14 mg tablet
Company Formulation ID FDA Description
Genzyme Corporation F20999 Lactose monohydrate; Fd&c blue no. 2; Magnesium stearate; Talc; Titanium dioxide; Hydroxypropyl cellulose (1200000 mw); Hypromellose, unspecified; Microcrystalline cellulose; Polyethylene glycol, unspecified; Sodium starch glycolate type a corn; Starch, corn
------------------------------------------------------------------------------------

References

1 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
2 Teriflunomide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6844).